In this article, we will discuss the 10 Best Growth Stocks Under $10 to Invest In.
On April 22, Andrew Slimmon, Morgan Stanley Investment Management senior portfolio manager, joined CNBC’s ‘Squawk Box’ to discuss the current state of the market and its various influences. Slimmon explained that the market is currently pivoting between micro factors (such as exceptionally strong earnings revisions) and macro concerns (including the Iran conflict, AI disruption, and private credit). He noted that while the market recently saw a 9% decline followed by a 12% rally, it is currently in an overbought state, moving toward a consensus EPS target of $375 for next year. Slimmon argued that a P/E multiple of 20 is reasonable, which would place the market around the 7,500 level, despite current fluctuations between macro-driven washouts and micro-driven gains.
NASDAQ recently saw a rapid recovery and saw 13 straight up days. Slimmon attributed this to muscle memory, explaining that investors who turned negative and missed out on last year’s rally are determined not to repeat that mistake. This desire to buy the dip has prevented a deeper sell-off this year, as many market participants now have egg on their faces from their previous hesitation. He remains optimistic that geopolitical headlines will not cause a major decline because the market has learned to look past them. Regarding AI, Slimmon disagreed with the idea that AI is solely a driver of higher prices due to anticipated future benefits. He pointed out that while major companies are increasing CapEx for AI, they have yet to show the actual returns or cost savings that drive the S&P. He compares the current skepticism toward AI spending to the mid-1990s, when the market first focused on the industries that the internet would disrupt (such as newspapers and publishers) before realizing the massive profitability and margin expansion it would eventually provide.
Our Methodology
We used screeners to identify stocks that have a record of delivering earnings growth and have grown their EPS by at least 20% over the past 3 years. We then selected stocks that are trading below $10 per share, and limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.
Note: All data was sourced on April 23.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
10 Best Growth Stocks Under $10 to Invest In
10. Paysafe Limited (NYSE:PSFE)
Paysafe Limited (NYSE:PSFE) is one of the best growth stocks under $10 to invest in. On April 22, Paysafe officially launched PaysafeWallet, a digital wallet designed to bridge the gap between cash-based and digital-preferred consumers within the experience economy. Fully integrated into the existing PaysafeCard app and website, this new offering represents the evolution of the company’s previous account and card services into a full-service financial platform.
The rollout establishes a unified brand identity for the company’s consumer-facing financial tools across all active markets. The digital wallet provides customers with the ability to send, receive, spend, and withdraw funds, supported by a dedicated IBAN-enabled personal payment account and a debit card. Currently live across 18 European markets, PaysafeWallet enables a seamless transition from traditional cash solutions to modern digital banking.
More than 600,000 existing customers will maintain uninterrupted access to their current services while the platform expands into new regions where PaysafeCard is already established. Chief Product Officer Bob Legters highlighted that PaysafeWallet is a core component of the company’s future strategy, connecting cash-based users to essential digital financial services.
Paysafe Limited (NYSE:PSFE) is a global payments platform offering digital wallets, payment processing, and online cash solutions, particularly within specialized verticals such as entertainment and iGaming.
9. Riskified Ltd. (NYSE:RSKD)
Riskified Ltd. (NYSE:RSKD) is one of the best growth stocks under $10 to invest in. On April 7, Riskified and Outpayce from Amadeus launched a partnership to integrate AI-powered fraud prevention and chargeback protection into Outpayce’s travel payment platform. As a global travel payments orchestrator, Outpayce enables airlines to streamline complex transactions, and this collaboration marks the first time a chargeback guarantee solution has been integrated into its ecosystem.
The partnership provides carriers with revenue predictability through guaranteed approval rates while reducing the high operational costs associated with travel fraud. The collaboration specifically addresses the perfect storm of risks in the airline industry, such as high ticket values and frequent card-not-present transactions, which have recently seen a 14% increase in risk. Riskified’s tech replaces traditional rules-based systems with ML that analyzes global merchant data to provide precise, automated decisions in real-time. This minimizes manual reviews and protects airlines from the financial impact of fraud.
A major Asia-Pacific international airline is scheduled to be the first merchant to go live with the integration in 2026, setting the stage for wider global adoption. By combining Outpayce’s specialized fintech infrastructure with Riskified Ltd.’s (NYSE:RSKD) risk intelligence, the two companies aim to enhance the traveler journey through more seamless and secure checkout experiences.
Riskified Ltd. (NYSE:RSKD) and its subsidiaries develop and offer an e-commerce risk intelligence platform that allows online merchants to create trusted relationships with consumers in the US, Europe, the Middle East, Africa, the Asia-Pacific, and the Americas.
8. Allogene Therapeutics Inc. (NASDAQ:ALLO)
Allogene Therapeutics Inc. (NASDAQ:ALLO) is one of the best growth stocks under $10 to invest in. On April 21, Allogene Therapeutics received regulatory clearance to expand its pivotal Phase 2 ALPHA3 study of cemacabtagene ansegedleucel (cema-cel) into South Korea and Australia. This expansion increases the trial’s global footprint to over 80 sites, up from the current 60 in North America, with patient screening and enrollment in these new regions expected to begin in Q2 2026.
The study evaluates cema-cel as a first-line consolidation treatment for patients with large B-cell lymphoma/LBCL who show minimal residual disease/MRD after initial chemotherapy. The decision to expand follows positive interim futility analysis data from the first 24 patients, which showed that cema-cel achieved a 58.3% MRD clearance rate compared to just 16.7% in the standard-of-care observation group. Additionally, the therapy was well-tolerated with no reported cases of cytokine release syndrome or neurotoxicity.
Allogene Therapeutics Inc. (NASDAQ:ALLO) aims to enroll ~220 patients in the ALPHA3 trial by the end of 2027. An interim analysis of event-free survival is planned for mid-2027, with the primary analysis following in mid-2028 to potentially support a BLA submission. Cema-cel, which has already received the RMAT designation from the FDA, represents a next-generation off-the-shelf AlloCAR T product designed to address the 30% of LBCL patients who typically relapse under the current watch-and-wait standard of care.
Allogene Therapeutics Inc. (NASDAQ:ALLO) is a clinical-stage biotechnology company dedicated to the development of off-the-shelf allogeneic CAR-T cell therapies for cancer and autoimmune diseases. The company’s goal is to provide a scalable, readily available cell therapy derived from healthy donors.
7. MeiraGTx Holdings (NASDAQ:MGTX)
MeiraGTx Holdings (NASDAQ:MGTX) is one of the best growth stocks under $10 to invest in. On April 16, MeiraGTx Holdings entered into an asset purchase agreement with Johnson & Johnson to reacquire all interests in botaretigene sparoparvovec (bota-vec), a gene therapy for X-linked retinitis pigmentosa/XLRP. Under the terms of the deal, MeiraGTx will provide an upfront cash payment of $25 million, followed by milestone payments tied to US regulatory approval and sales performance, as well as royalties starting in 2029.
The company, which is already the commercial manufacturer for the product, intends to immediately begin filing for regulatory approval in the US, EU, and Japan, targeting a potential market launch in 2027. The acquisition follows compelling data from the Phase 3 LUMEOS study, which showed clinically meaningful and statistically significant improvements in retinal sensitivity and visual function.
While the primary endpoint regarding a maze-based mobility assessment did not meet statistical significance, secondary measures showed that 45% of treated patients gained 10 or more letters in low luminance visual acuity. Furthermore, 40% of treated subjects showed improvement across multiple vision domains. MeiraGTx Holdings (NASDAQ:MGTX) plans to use its existing manufacturing infrastructure and established relationships with global centers of excellence to bring bota-vec to the estimated 20,000 patients living with XLRP in the US and Europe.
MeiraGTx Holdings (NASDAQ:MGTX) is a clinical-stage biotechnology company that develops gene therapies for serious diseases. It uses viral vector technologies to target genetic disorders, ocular diseases, and neurodegenerative conditions to deliver durable, transformative treatments.
6. Geron Corporation (NASDAQ:GERN)
Geron Corporation (NASDAQ:GERN) is one of the best growth stocks under $10 to invest in. On April 13, Geron Corporation appointed Timothy Williams as Executive Vice President, Chief Legal Officer, and Corporate Secretary. A seasoned legal executive, Williams joins the commercial-stage biopharma firm from Vanda Pharmaceuticals, where he served as Senior Vice President and General Counsel for eight years. His professional background also includes leadership roles at AgNovos Bioscience and Stryker Corporation, as well as private practice experience at the law firms Mayer Brown and Bryan Cave.
President and CEO Harout Semerjian noted that Williams’ deep industry expertise and track record at commercial-stage organizations will provide invaluable strategic counsel. This appointment follows recent additions to the company’s Board of Directors, part of a broader effort to strengthen leadership as Geron works to establish itself as a leader in sustainable hematology.
Williams will oversee legal functions and corporate governance as the company advances its commercial strategy for treating lower-risk myelodysplastic syndromes. In his new role, Williams will support Geron Corporation’s (NASDAQ:GERN) priorities and long-term growth objectives. He expressed enthusiasm for the company’s differentiated treatment options and its potential to create value for both patients and shareholders.
Geron Corporation (NASDAQ:GERN) is a commercial-stage biotech company focused on developing therapeutic products for oncology.
While we acknowledge the potential of GERN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than GERN and that has 100x upside potential, check out our report about the cheapest AI stock.
Click to continue reading and see the 5 Best Growth Stocks Under $10 to Invest In.
Disclosure: None. None. Follow Insider Monkey on Google News.
